Android Apple

Mozart Therapeutics doses first patients in trial of MTX-101 for autoimmune diseases

By Yahoo! Finance   |   6 months ago
Mozart Therapeutics doses first patients in trial of MTX-101 for autoimmune diseases

US biopharmaceutical company Mozart Therapeutics has initiated Phase Ia/b trial of MTX-101, a potential treatment for autoimmune diseases.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.